D. Boral Capital Lowers Enlivex Therapeutics Rating to Hold
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 24 2025
0mins
Source: Benzinga
Real-time Intelligence: Benzinga Pro offers traders the fastest news alerts to stay updated on market movements.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.
Market Winning Tools: The platform provides essential tools and information that help traders succeed in the stock market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ENLV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ENLV
About ENLV
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Enlivex Therapeutics' RAIN Token Listed on KuCoin, Expected to Enhance Liquidity
- RAIN Token Listing: Enlivex Therapeutics reported that its RAIN token was listed on KuCoin on January 6, with KuCoin serving over 40 million users primarily in Southeast Asia, which is expected to enhance global market access and liquidity for RAIN.
- Digital Asset Strategy: Enlivex has launched a digital asset treasury strategy focused on acquiring RAIN tokens, aiming to implement the first RAIN prediction markets token treasury strategy while continuing to develop its core business operations.
- Market Potential Analysis: HC Wainwright noted that RAIN's unique 'buy and burn' mechanism could significantly reduce token supply, projecting that if prediction markets reach $1 trillion in annual volume, RAIN could burn approximately $1.25 billion worth of tokens by capturing a 5% market share.
- Analyst Rating Upgrade: Analyst Raghuram Selvaraju reiterated a 'Buy' rating for ENLV and raised the price target from $7 to $13, reflecting dilution from the recent PIPE transaction and incorporating the value of RAIN tokens on Enlivex's balance sheet.
Continue Reading
Enlivex Adopts First RAIN Prediction Market Token Strategy, Secures $212 Million Funding
- Successful Funding: Enlivex has successfully closed a $212 million private investment, which will be utilized to implement the RAIN prediction market token treasury strategy, thereby enhancing the company's competitiveness in the digital asset space.
- Innovative Strategy: By adopting RAIN tokens as its primary treasury reserve asset, Enlivex not only provides investors with exposure to emerging digital capital but also demonstrates its forward-thinking approach in blockchain technology applications.
- Market Potential: The clinical development of Allocetra™ targets knee osteoarthritis, affecting over 300 million people globally, with projections indicating that 78 million Americans will be impacted by 2040, highlighting the significant market demand and potential returns for this therapeutic solution.
- Leadership Enhancement: Former Italian Prime Minister Matteo Renzi joining the Enlivex Board brings extensive leadership experience and a deep understanding of innovation, further elevating the company's strategic vision and market influence.
Continue Reading